Inactive Instrument

CTI BioPharma Corp.

Equities

CTIC

US12648L6011

Biotechnology & Medical Research

Jack W. Singer Ceases to Be an Employee of CTI BioPharma Corp

September 06, 2018 at 11:07 am

On September 4, 2018, Dr. Jack W. Singer, Executive Vice President, Chief Scientific Officer, Interim Chief Medical Officer and Global Head of Translational Medicine of CTI BioPharma Corp. (Company), ceased to be an employee of the Company.

Latest news about CTI BioPharma Corp.

DRI Healthcare Trust Receives US$54.8 Million in Debt Repayment	26/06/23	MT
DRI Healthcare Trust Brief: Announcing US$54.8 Million Debt Repayment from CTI BioPharma Corp.	26/06/23	MT
DRI Healthcare Trust Announces USD 54.8 Million Debt Repayment from CTI Biopharma Corp	26/06/23	CI
Global markets live: Nvidia, IBM, Ford, Pfizer, Lucid Group...	26/06/23
Sobi Wraps Up $1.7 Billion Acquisition of CTI BioPharma	26/06/23	MT
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from NASDAQ Composite Index	26/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P Global BMI Index	26/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P Biotechnology Select Industry Index	26/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from S&P TMI Index	26/06/23	CI
Swedish Orphan Biovitrum Completes Tender for CTI BioPharma	26/06/23	MT
Swedish Orphan Biovitrum AB (OM:SOBI) completed the acquisition of CTI BioPharma Corp. from a group of shareholders.	25/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Microcap Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2000 Dynamic Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000E Growth Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000E Value Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000E Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2500 Growth Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Completeness Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2000 Value Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2000 Growth Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 2500 Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Microcap Value Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000 Value Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell Small Cap Comp Growth Index	23/06/23	CI
CTI BioPharma Corp.(NasdaqCM:CTIC) dropped from Russell 3000 Growth Index	23/06/23	CI

Chart CTI BioPharma Corp.

Duration

Period

More charts

Company Profile

CTI BioPharma Corp. is a commercial biopharmaceutical company. It is focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers. Its commercially approved product, VONJO (pacritinib), is an oral kinase inhibitor with specificity for JAK2, mutant JAK2 form, IRAK1, ACVR1 (ALK2) and FLT3 for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. It is conducting the Phase III PACIFICA study of pacritinib in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. In addition to myelofibrosis, the kinase profile of pacritinib suggests its potential therapeutic utility in conditions, such as acute myeloid leukemia, myelodysplastic syndrome, chronic myelomonocytic leukemia, graft versus host disease (GvHD) and chronic lymphocytic leukemia (CLL) due to its inhibition of JAK2, IRAK1, FLT3, ACVR1 and CSF1R.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.63%	50.93B
IQVIA HOLDINGS INC.	-0.09%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-4.96%	29.18B
ICON PUBLIC LIMITED COMPANY	+11.18%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.95%	18.9B
BIO-TECHNE CORPORATION	+8.61%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.73%	12.17B
MEDPACE HOLDINGS, INC.	+28.31%	12.16B

Other Biotechnology & Medical Research